UNSPSC 51312806: Methiomeprazine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2R9QTF0OL, chemically known as 10h-phenothiazine-10-propanamine, n,n, .beta.-trimethyl-2- (methylthio)-, monohydrochloride but generally known as methiomeprazine, which bears US NIH Compound Identifier 26430. European Medicines Agency schedules Methiomeprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08849MIG.

UNSPSC 51312806 Methiomeprazine is a Commodity code that represents a specific pharmaceutical ingredient, yet recent state and local opportunities tagged under this code do not align with procurement of methiomeprazine itself. Instead, the code shows activity in broader pharmaceutical and drug-related products: naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health agencies and cooperative purchasing vehicles. The actual buying reflects community health initiatives, pharmacy benefit management, and opioid-response programming rather than purchase of the named active ingredient. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering agreements across state and local government facilities in Minnesota and Oregon).

Recent opportunities span Florida, Texas, and the Minnesota–Oregon corridor. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the procurement specified e-procurement portal submission, E-Verify compliance, and a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co. with evaluation weighted 75 percent on price competitiveness and required cGMP and DSCSA compliance. The code shows minimal alignment with its nominal scope and little recent activity specific to methiomeprazine procurement.